Abstract
The efficacy of fluconazole, a new bis-triazole antifungal agent, was compared with that of orally administered ketoconazole and parenterally administered amphotericin B against aspergillus and cryptococcus infections in mice. Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B.
MeSH terms
-
Amphotericin B / therapeutic use
-
Animals
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy*
-
Aspergillus flavus / drug effects
-
Aspergillus fumigatus / drug effects
-
Brain Diseases / drug therapy
-
Cryptococcosis / drug therapy*
-
Female
-
Fluconazole
-
Ketoconazole / therapeutic use
-
Lung Diseases, Fungal / drug therapy
-
Mice
-
Opportunistic Infections / drug therapy
-
Triazoles / therapeutic use*
Substances
-
Antifungal Agents
-
Triazoles
-
Amphotericin B
-
Fluconazole
-
Ketoconazole